260 related articles for article (PubMed ID: 21236645)
1. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
Bryant AM; Slain D; Cumpston A; Craig M
Int J Antimicrob Agents; 2011 Mar; 37(3):266-9. PubMed ID: 21236645
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.
Ross AL; Slain D; Cumpston A; Bryant AM; Hamadani M; Craig M
Int J Antimicrob Agents; 2012 Dec; 40(6):557-61. PubMed ID: 23068599
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
AbuTarif MA; Krishna G; Statkevich P
Curr Med Res Opin; 2010 Feb; 26(2):397-405. PubMed ID: 20001450
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.
Hoenigl M; Raggam RB; Salzer HJ; Valentin T; Valentin A; Zollner-Schwetz I; Strohmeier AT; Seeber K; Wölfler A; Sill H; Krause R
Int J Antimicrob Agents; 2012 Jun; 39(6):510-3. PubMed ID: 22481057
[TBL] [Abstract][Full Text] [Related]
6. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
Selvy N; Villiet M; Hansel-Esteller S
Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
8. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.
Eiden C; Meniane JC; Peyrière H; Eymard-Duvernay S; Le Falher G; Ceballos P; Fegueux N; Cociglio M; Reynes J; Hillaire-Buys D
Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):161-7. PubMed ID: 21611869
[TBL] [Abstract][Full Text] [Related]
10. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.
Crombag MR; Huisman C; Kemper EM; Brüggemann RJ; Bijleveld YA
Ther Drug Monit; 2012 Jun; 34(3):320-5. PubMed ID: 22561586
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
Gross BN; Ihorst G; Jung M; Wäsch R; Engelhardt M
Pharmacotherapy; 2013 Oct; 33(10):1117-25. PubMed ID: 23864486
[TBL] [Abstract][Full Text] [Related]
15. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.
Müller C; Arndt M; Queckenberg C; Cornely OA; Theisohn M
Mycoses; 2006; 49 Suppl 1():17-22. PubMed ID: 16961577
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
Hummert SE; Green MR
Ther Drug Monit; 2015 Aug; 37(4):508-11. PubMed ID: 25549205
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
Chin A; Pergam SA; Fredricks DN; Hoofnagle AN; Baker KK; Jain R
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760896
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
19. Optimising absorption of posaconazole.
Green MR; Woolery JE
Mycoses; 2011 Nov; 54(6):e775-9. PubMed ID: 21615538
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?
Girmenia C; Annino L; Mariotti B; Fanci R; Minotti C; Spadea A; Carotti A; Piedimonte M; Chierichini A; Cerchiara E; Caselli D; Cupelli L; Arcioni F; Bertaina A; Ribersani M; Proia A; Mengarelli A; Perriello V; Torelli GF; Di Gioia M; Del Principe MI; Cassetta MI; Fallani S; Novelli A
Med Mycol; 2016 Jul; 54(5):445-58. PubMed ID: 26868905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
